Studies on the pressor responses produced by bradykinin and kallidin

Bradykinin increases BP in endotoxemic rat: functional and biochemical evidence of angiotensin II AT1 /bradykinin B2 receptor heterodimerization

BACKGROUND AND PURPOSE

Bradykinin may induce vasoconstriction in selected vessels or under specific experimental conditions. We hypothesized that inflammatory stimuli, such as endotoxin challenge, may induce the dimerization of AT₁ /B₂ receptors, altering the vascular effects of bradykinin.

EXPERIMENTAL APPROACH

Wistar rats received LPS (1 mg·kg^-1 , i.p.) and were anaesthetized for assessment of BP. Mesenteric resistance arteries were used in organ baths and subjected to co-immunoprecipitation and Western blot analyses.

KEY RESULTS

At 24 and 48 hr after LPS, bradykinin-induced hypotension was followed by a sustained increase in BP, which was not found in non-endotoxemic animals. The B₂ receptor antagonist Hoe-140 fully blocked the responses to bradykinin. The pressor effect of bradykinin was not prevented by prazosin, an α₁ -adrenoceptor antagonist, but it was inhibited by the AT₁ receptor antagonist losartan or the Rho-kinase inhibitor Y-27632. Endotoxemic rats also displayed enhanced pressor responses to angiotensin II, which were blocked by Hoe-140. Co-immunoprecipitation isolated using anti-B₂ or anti-AT₁ receptor antibodies showed that resistance arteries presented augmented levels of the AT₁ /B₂ receptor complexes at 24 hr after LPS injection. The presence of AT₁ /B₂ receptor heterodimers did correlate with the development of losartan-sensitive contractile responses to bradykinin and potentiation of angiotensin II-induced contraction, which was prevented by Hoe-140.

CONCLUSIONS AND IMPLICATIONS

Endotoxin challenge is a stimulus for AT₁ /B₂ receptor heterodimerization in native vessels and shifts the B₂ receptor-dependent vascular effect of bradykinin to a more complex pathway, which also depends on AT₁ receptors and their intracellular signalling pathways.

Angiotensin converting enzyme-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human 'new pressor protein' related to coagulation beta-factor XIIa

BACKGROUND

Human 'new pressor protein' (NPP), related to coagulation beta-factor XIIa (beta-FXIIa), potently releases sympathoadrenal catecholamines in bioassay rats, with concurrent elevation of systolic and diastolic blood pressure (SBP/DBP) and heart rate (HR). Elevated plasma NPP/beta-FXIIa levels in hypertensive anephric pediatric patients on hemodialysis associated with fluid status and blood pressure changes were previously reported, suggesting that NPP/beta-FXIIa contributed to their hypertension.

OBJECTIVE

To investigate the mechanism of action of NPP/beta-FXIIa.

METHODS

Hemodynamic and sympathoadrenal responses to NPP (20 microL plasma equivalent/rat) or coagulation beta-FXIIa (300 ng/kg intravenously) were measured in rats treated with pentolinium (ganglion blockade [+GB]) and/or captopril (+CAP; angiotensin converting enzyme [ACE] inhibition).

RESULTS

In controls not receiving GB or CAP (-GB-CAP), NPP/beta-FXIIa raised plasma epinephrine (E) sixfold, SBP/DBP by 14/8 mmHg and HR by 15 beats/min. With blockade of the cholinergic pathway to the sympathoadrenal system (+GB), basal E, norepinephrine (NE), SBP, DBP and HR all dropped. However NPP/beta-FXIIa remained capable of raising E 20-fold, NE fourfold, SBP/DBP by 27/11 mmHg and HR by 20 beats/min, suggesting that it acted through a 'noncholinergic' mechanism. With +CAP alone, NPP/beta-FXIIa raised plasma E 18-fold, NE threefold, SBP/ DBP by 29/8 mmHg and HR by 73 beats/min, implicating an ACE-regulated 'peptidergic' mechanism. Combining +GB with +CAP potentiated NPP/beta-FXIIa actions further by raising E 50-fold, NE sevenfold, SBP/DBP by 55/20 mmHg and HR by 87 beats/min, strengthening the efficacy of this alternate pathway.

CONCLUSIONS

The cardiovascular effects of NPP/beta-FXIIa are considerably mediated by a noncholinergic (peptidergic) ACE-regulated mechanism for sympathoadrenal catecholamine release that is enhanced by +GB and/or +CAP. Under inflammatory procoagulant conditions, endogenously produced NPP/beta-FXIIa may interfere with the antihypertensive effects of ACE inhibition therapy.

Changes in blood glucose and plasma insulin levels induced by bradykinin in anaesthetized rats

1. The influence of bradykinin (BK) on blood glucose and plasma insulin levels was investigated in anaesthetized rats. 2. Blood glucose level was dose-dependently increased by intravenous infusion of BK. This effect of BK was enhanced by captopril, an inhibitor of angiotensin-converting enzyme (ACE). Des-Arg9-bradykinin (DABK), a kinin B1 receptor agonist, did not modify blood glucose levels while the effect of BK was inhibited by Hoe-140, a kinin B2 receptor antagonist. 3. The effect of BK was reduced by the NO-synthase inhibitor, N(omega)-nitro-L-arginine methyl ester (L-NAME), and by the cyclo-oxygenase inhibitor, indomethacin. The effect of BK was suppressed by the association of propranolol with phentolamine or phenoxybenzamine. It was also reduced by hexamethonium, a ganglion-blocking drug. In adrenalectomized rats, the infusion of BK slightly decreased blood glucose levels. 4. The hyperglycaemic effect of adrenaline was suppressed by propranolol associated with phentolamine or phenoxybenzamine, but it was not modified by L-NAME. 5. Infusion of BK did not modify plasma insulin levels. However, after phentolamine and propranolol, BK induced a transient 2 fold rise in plasma insulin levels. The release of insulin was dose-dependent and inhibited by Hoe-140. 6. We conclude that infusion of BK induces, via a stimulation of B2 receptors, the release of NO and of prostanoids. The latter agents activate through a reflex pathway the release of catecholamines from the adrenal medulla. This release increases blood glucose levels and reduces plasma insulin levels. After adrenoceptor inhibition, BK induces a secretion of insulin, via the stimulation of B2 receptors.

Investigation of the haemodynamic effects of Phoneutria nigriventer venom in anaesthetised rabbits

The haemodynamic alterations induced by the central and peripheral administration of the armed spider (Phoneutria nigriventer) venom (PNV) were investigated in anaesthetised rabbits. The intracerebroventricular injection of increasing doses of PNV (30 and 100 microg/kg) elicited a biphasic cardiovascular response characterised by a brief hypotension (1-3 min) followed by a marked and sustained (more than 30 min) increase in mean arterial pressure (61 +/- 5 and 61 +/- 10%, respectively) and in systemic vascular resistance (135 +/- 21 and 161 +/- 37%) accompanied by mild increases in cardiac contractility. Systemic alterations such as salivation and muscular fasciculation were also observed. At the opposite, the dose of 100 microg/kg of PNV injected intravenously produced only a hypotensive effect (29 +/- 4% decrease in mean arterial pressure) and a decrease in vascular resistance (38 +/- 5%). Nevertheless, a much higher dose of PNV (1 mg/kg) injected intravenously produced a hypertensive response analogous to the one observed upon central administration. The central hypertensive response induced by PNV was not affected by preteating the animals with selective antagonists of receptors of different neurotransmitters or endogenous mediators such as: acethylcoline muscarinic, bradykinin B2, angiotensin II AT1 receptors and also antagonists of the excitatory amino acid receptors of the central nervous system. Nevertheless, the intravenous pretreatment with the selective alpha1-adrenergic receptor antagonist prazosin significantly blunted the excitatory cardiovascular response evoked by the central injection of PNV. It is concluded that PNV can induce central as well as peripheral haemodynamic effects. The central component seems to be mediated by the activation of cardiovascular centres which in turn lead to an increase in the sympathetic outflow to the periphery, whereas the peripheral component can be accounted for either by direct activation of the vascular alpha1-adrenergic receptors or by catecholamine release from the sympathetic nerve endings.

Distribution of bradykinin B2 receptors in sheep brain and spinal cord visualized by in vitro autoradiography

Bradykinin B2 receptors were localized in the sheep brain and spinal cord by quantitative in vitro autoradiography using a radiolabelled and specific bradykinin B2 receptor antagonist analogue, 3-4-hydroxyphenyl-propionyl-D-Arg0-[Hyp3,Thi5,D-Tic 7,Oic8]bradykinin, (HPP-HOE 140). This radioligand displays high affinity and specificity for bradykinin B2 receptors. The respective K(i) values of 0.32, 1.37 and 156 nM were obtained for bradykinin, HOE140 and D-Arg[Hyp3,D-Phe7,Leu8]bradykinin competing for radioligand binding to lamina II of sheep spinal cord sections. Using this radioligand, we have demonstrated the distribution of bradykinin B2 receptors in many brain regions which have not been previously reported. The highest density of bradykinin B2 receptors occur in the pleoglial periaqueductal gray, oculomotor and trochlear nuclei and the circumventricular organs. Moderate densities of receptors occur in the substantia nigra, particularly the reticular part, the posterior thalamic and subthalamic nuclei, zona incerta, the red and pontine nuclei, some of the pretectal nuclei and in discrete layers of the superior colliculus. In the hindbrain, moderate levels of bradykinin B2 receptor binding occur in the nucleus of the solitary tract, and in spinal trigeminal, inferior olivary, cuneate and vestibular nuclei. Laminae II, X and dorsal root ganglia display the most striking binding densities in the spinal cord, while the remainder of the dorsal and ventral horn display a low and diffuse density of binding. Bradykinin B2 receptors are extensively distributed throughout the sheep brain and spinal cord, not only to sensory areas but also to areas involved in motor activity.

The action of Hoe 140 on the bradykinin-induced splenic pressor reflex of the anaesthetized cat

1. Intrasplenic injection of bradykinin (BK) induced a dose-dependent pressor response in the anaesthetized cat, with an ED50 of 0.98 +/- 0.43 nmol. In contrast, intrasplenic administration of desArg9bradykinin (desArg9BK) was without significant effect at doses of up to 200 nmol. 2. Intravenously administered BK induced a dose-dependent depressor response in the anaesthetized cat, with an ED50 of 0.86 +/- 0.09 nmol kg-1. desArg9BK was again without significant effect in this system at doses of up to 200 nmol kg-1. 3. Both the pressor and depressor responses to BK were antagonized to a similar degree in a dose-dependent manner by Hoe 140 (10 and 100 nmol kg-1, i.v.). 4. At these doses, Hoe 140 appears to be a specific BK antagonist as it was ineffective against pressor responses to intrasplenic injection of capsaicin (5 nmol), while blocking those to an approximately equieffective dose of BK (1 nmol) in a dose-dependent fashion. 5. Both the pressor response to intrasplenic BK and the depressor response to intravenous BK in the anaesthetized cat appear to be mediated by B2-receptors. This model may be useful in the quantitative determination of the antinociceptive potency of BK antagonists.

Kinin receptors of the central nervous system of spontaneously hypertensive rats related to the pressor response to bradykinin

1. Kinin analogues bradykinin (BK), T-kinin, Met-Lys-BK, Lys-Lys-BK, Des-Arg9-BK with agonist activity and D-Arg0-Hyp3-Thi5,8-D-Phe7-BK (DAHTDBK) and Arg9-Leu8-BK with antagonist activity were injected into the posterior portion of the fourth cerebral ventricle of unanaesthetized rats implanted with permanent cannulae and arterial pressure was measured directly from the abdominal aorta. 2. The spontaneously hypertensive rats (SHR) were more sensitive than normotensive Wistar rats (NWR) to the pressor effect of BK and other kinin analogues. The SHR did not differ in sensitivity of the pressor response to centrally administered angiotensin II or endothelin-1. 3. Experiments with selective kinin agonists and antagonists revealed that in the SHR, as in the NWR, the receptors which mediated the central pressor response are of the BK2 subtype. 4. Measurements of the pressor activity of kinins with different degrees of susceptibility to degradation, as well as experiments with kininase inhibitors, enalaprilat and CPP-Ala-Ala-Phe-pAB, suggest that the kininase activity in the central nervous system of SHR is reduced in comparison to that of NWR. 5. The SHR also showed increased sensitivity to BK and Lys-Lys-BK, compared with the NWR, when the kinins were injected following the administration of a mixture of the kininase inhibitors, suggesting that mechanisms other than kininase activity may play a role in the increased sensitivity of the SHR to the central pressor action of kinins. 6. An in vivo characterization of the kinin receptors which mediate the central pressor response showed that the interaction with DAHTDBK was reversible and of competitive nature. The pA2 in vivo estimated for the kinin receptors of the SHR was 0.7 logarithm units larger than that obtained in the NWR. 7. The kinin receptors which mediate the central BK pressor effect in the SHR are of the BK2 subtype and are similar to receptors in the NWR. The increased sensitivity to kinins in the SHR may be explained, at least in part, by their decreased kininase activity. At present it is impossible to conclude whether the difference observed in the pA2 represents an increased affinity of the kinin receptors or can be attributed to differences amongst strains in the enzymatic degradation of the antagonist.

Central nervous system kinin receptors and the hypertensive response mediated by bradykinin

1. Bradykinin (Bk) administered intracerebroventricularly to the rat causes an increase in arterial pressure. 2. Analogues of Bk with agonist and antagonist activity were injected, over a wide dose-range, into the posterior region of the fourth ventricle of unanaesthetized rats implanted with permanent ventricular canullae, and blood pressure was measured directly from the abdominal aorta. 3. The analogues Ile-Ser-Bk (T-kinin) and Lys-Lys-Bk, which interact with both B1 and B2 Bk receptors, produced pressor effects similar to those of Bk, although of greater duration, whereas des-Arg9-Bk, a B1-receptor agonist, had no effect. 4. The B1-antagonist des-Arg9-[Leu8]-Bk did not alter the Bk pressor response, but D-Arg-[Hyp3, Thi5,8,D-Phe7]-Bk, which interacts both with B1- and B2-receptors blocked the responses to Bk, T-kinin and Lys-Lys-Bk and caused parallel shifts to the right of the Bk dose-response curves. Neither antagonist, by itself, had any effect on blood pressure. 5. It is concluded that the central pressor response to Bk is mediated by receptors of the B2 subtype.

The involvement of the sympathetic nervous system in the centrogenic pressor and tachycardiac effects of prostaglandins E2 and F2 alpha in anaesthetised cats

The intracerebroventricular (i.c.v.) administration of prostaglandin E2 (PGE2, 1 micrograms) and prostaglandin F2 alpha (PGF2 alpha, 10 micrograms) produced prolonged pressor and tachycardiac responses in chloralose-anaesthetised cats. Phenoxybenzamine-pretreatment completely prevented the pressor response without altering the tachycardiac response, whereas propranolol intervention completely inhibited the tachycardiac response and also attenuated the pressor response. The pretreatment with pentolinium completely antagonised both the pressor and tachycardiac responses to i.c.v. PGE2 and PGF2 alpha. The results suggest that the centrally administered PGE2 and PGF2 alpha augment sympathetic outflow to the heart and vascular system and thereby cause excitatory cardiovascular responses in anaesthetised cats.

Interrelationship between central bradykinin and vasopressin in conscious rats

Intracerebroventricular administration of bradykinin (1, 5 and 20 micrograms) into conscious rats resulted in significant dose-dependent increases in the plasma vasopressin concentration, mean arterial blood pressure and heart rate. Peripheral blockade of the pressor action of vasopressin with a vasopressin pressor antagonist (10 micrograms/kg, i.v.) did not cause an attenuation but rather a potentiation and prolongation of the pressor effects of central bradykinin (20 micrograms). Central administration of the vasopressin antagonist (150 ng) caused no peripheral blockade of the pressor effects of exogenous i.v. vasopressin but almost abolished the bradykinin-induced tachycardia, with little effect on the pressor effects of central bradykinin (20 micrograms). The results indicate that centrally administered bradykinin stimulates vasopressin release into the plasma and that central vasopressin may modulate the cardiovascular actions of central bradykinin.

Bradykinin and related peptides in central control of the cardiovascular system

The evidence for a brain kallikrein-kinin system and for the possible role for kinins in brain control of the cardiovascular system are reviewed. All components of the kallikrein-kinin system are present in brain and kinins have a variety of cardiovascular actions of central origin following peripheral, intracerebroventricular or brain parenchymal administration. How components of the brain kallikrein-kinin system are regulated or even whether they function as a system remains to be established. However, bradykinin does fulfill several of the criteria necessary for establishing a substance as a neurotransmitter and these are discussed.

Effects of bradykinin and autonomic nervous system inhibition on systemic and regional hemodynamics in the unanesthetized rhesus monkey

Studies were performed in unanesthetized monkeys to determine if bradykinin infusions reproduce the circulatory events of early endotoxemia. Kinin infusions before and during autononiic ganglionic blockade with trimethaphan were significantly correlated (P <0.05) with decreases in mean arterial pressure. Kinin infusion at 15-18, µg/kg min - produced 26 mm Hg fall in mean blood pressure at 3 min, due to fall in total peripheral resistance of 14 mm Hg/liter min -1 . Heart rate rose 23 beats/min. After 10 minutes of infusion, peripheral resistance had returned to base line, blood pressure remained low due to fall in cardiac output of 0.53 liters/min (P <0.01). Ganglionic blockade prevented recovery of resistance. Plasma bradykinin levels at 3 and 10 minutes were 14 and 15 µg/ml, respectively. Regional and systemic hemodynamic effects of kinin (15-18 µg/kg min were determined in 10 monkeys. After 10 minutes of infusion, bradykinin produced systemic effects. Regional flow measurement (by radioactive microsphere technique) demonstrated a pattern similar to that seen during hemorrhage. Canglionic blockade lowered mean arterial pressure 33 mm Hg by generalized vasodilatation, Kinin infusion then resulted in further vasodilatation and fall in blood pressure of 12 mm Hg, and cardiac output of 0.74 liters/min. Regional flow distribution during combined infusion was similar to that seen during early endotoxemia.

The action of ranatensin, a new polypeptide from amphibian skin, on the blood pressure of experimental animals

1. The blood pressure response to ranatensin, an undecapeptide from the skin of the frog, Rana pipiens, has been studied in various experimental animals.2. Ranatensin raised blood pressure in the dog and rabbit. The response was not altered by atropine, phentolamine, propranolol or hexamethonium, suggesting a direct peripheral vasoconstrictor action. In both animals ranatensin was about one-tenth as potent as angiotensin. Tachyphylaxis to ranatensin did occur, but there was no cross-tachyphylaxis with angiotensin, bradykinin, or noradrenaline.3. The peptide lowered blood pressure in the monkey, being as potent as eledoisin. The response was not altered by atropine, phentolamine, propranolol, tripelennamine, tetraethylammonium, bretylium, or methysergide. This again suggests a direct peripheral action on vascular smooth muscle. There was no tachyphylaxis to the depressor action, nor was there cross-tachyphylaxis with angiotensin, eledoisin, bradykinin, or noradrenaline.4. Ranatensin did not alter the blood pressure in cats and had a variable action in the guinea-pig with a rapid onset of tachyphylaxis.5. Ranatensin has a variable effect on the blood pressure in the rat that is related to the basal level of blood pressure. When the blood pressure is high, the response to the peptide is hypotension. Ranatensin raises blood pressure in the rat when the basal blood pressure is low. The pressor response to ranatensin appears to be due, in part, to the release of noradrenaline from peripheral sympathetic nerve endings.6. The composite action of ranatensin on blood pressure of various experimental animals is unlike that of any other peptide. Its hypertensive action in the dog or rabbit, together with a potent hypotensive action in the monkey, readily distinguishes it from all other vasoactive peptides.

Cardiovascular effects of prostaglandins mediated by the central nervous system of the dog

1. Prostaglandins A(1), E(1), F(1alpha) and F(2alpha) were infused into the vertebral artery of the chloralose-anaesthetized greyhound and the resulting cardiovascular responses were compared with those obtained on intravenous and intracarotid infusions in the same dose range.2. Infusions of PGF(2alpha) intravertebrally (4-64 (ng/kg)/min) caused an increase of blood pressure, tachycardia and a fall of central venous pressure. Cardiac output was increased and peripheral resistance was essentially unchanged. There was never any response to intravenous or intracarotid PGF(2alpha) infusions in this dose range.3. PGF(1alpha) was found to have similar effects to PGF(2alpha) but it was much less potent.4. PGE(1) infusions (4-360 (ng/kg)/min) into the vertebral artery caused a tachycardia which was greater than that obtained with intracarotid or intravenous infusions, but there was no significant effect on blood pressure.5. Infusions of PGA(1) caused a small fall of blood pressure accompanied by an increase of heart rate and the dose response relationships were similar for all three routes of administration.6. It is concluded that some prostaglandins can activate cardioregulatory centres within the territory of distribution of the vertebral artery. Prostaglandin F(2alpha) is the most potent of these.

The action of certain haloalkylamines on some biological activities of bradykinin

1. Bradykinin and histamine reduced the blood pressure in normotensive anaesthetized rabbits. They produced a pressor or biphasic response when the initial arterial pressure was lowered by acute haemorrhagic shock or mecamylamine blockade. When blood pressure was lowered by pretreatment with reserpine, bradykinin remained depressor and histamine produced a biphasic response.2. Phenoxybenzamine abolished the pressor responses to bradykinin and histamine, but potentiated and prolonged the depressor response to bradykinin.3. Phenoxybenzamine-OH and SY28-OH modified neither the pressor nor depressor responses to histamine, nor the pressor response to bradykinin. However, they greatly potentiated and prolonged the hypotensive effect of bradykinin.4. In the isolated rabbit ear preparation, the initial vascular tone influenced the responses to bradykinin and histamine. In preparations having low vascular tone they were vasoconstrictors, but when the tone was raised by angiotensin or noradrenaline, they were vasodilators.5. Phenoxybenzamine blocked the vasconstrictor effect of bradykinin in a rabbit ear preparation having low vascular tone and phenoxybenzamine or its related ethanolamine potentiated the vasodilator response to bradykinin in preparations in which the tone was high.6. The significance of these findings is discussed.